A Multicenter, Randomized, Double-Blind, 8-Week Comparative Trial of Standard Doses of Esomeprazole (40 mg) and Omeprazole (20 mg) for the Treatment of Erosive Esophagitis
Authors:
- 27 April 2006
- journal article
- research article
- Published by Springer Nature in Digestive Diseases and Sciences
- Vol. 51 (5) , 844-850
Abstract
To compare esomeprazole with omeprazole for healing erosive esophagitis (EE), 1148 patients with endoscopically confirmed EE were randomized to once-daily esomeprazole, 40 mg, or omeprazole, 20 mg, for 8 weeks in this multicenter, double-blind, parallel-group trial. The primary outcome was the proportion of patients with healed EE at week 8. Secondary outcomes included diary and investigator assessments of heartburn symptoms. At week 8, estimated healing rates were 92.2% (95% CI, 89.9%–94.5%) with esomeprazole and 89.8% (95% CI, 87.2%–92.4%) with omeprazole. Healing rates with esomeprazole were significantly higher than those with omeprazole at weeks 8 (88.4% vs 77.5%; P = 0.007) and 4 (60.8% vs 47.9%; P = 0.02) in patients with moderate to severe (Los Angeles grade C or D) EE at baseline but were not significantly different for patients with mild (Los Angeles grade A or B) EE. Both treatments were comparable for other secondary measures and had similar tolerability profiles.Keywords
This publication has 21 references indexed in Scilit:
- Efficacy of esomeprazole 40 mg vs. lansoprazole 30 mg for healing moderate to severe erosive oesophagitisAlimentary Pharmacology & Therapeutics, 2005
- Pharmacokinetic Studies with Esomeprazole, the (S)-Isomer of OmeprazoleClinical Pharmacokinetics, 2001
- Esomeprazole improves healing and symptom resolution as compared with omeprazole in reflux oesophagitis patients: a randomized controlled trialAlimentary Pharmacology & Therapeutics, 2000
- Esomeprazole provides improved acid control vs. omeprazole in patients with symptoms of gastro‐oesophageal reflux diseaseAlimentary Pharmacology & Therapeutics, 2000
- Endoscopic assessment of oesophagitis: clinical and functional correlates and further validation of the Los Angeles classificationGut, 1999
- Double‐blind, placebo‐controlled comparison of rabeprazole 20 mg vs. omeprazole 20 mg in the treatment of erosive or ulcerative gastro‐oesophageal reflux diseaseAlimentary Pharmacology & Therapeutics, 1999
- An evidence-based appraisal of reflux disease management — the Genval Workshop ReportGut, 1998
- Relation between oesophageal acid exposure and healing of oesophagitis with omeprazole in patients with severe reflux oesophagitis.Gut, 1996
- Pantoprazole and omeprazole in the treatment of reflux oesophagitis: a European multicentre studyAlimentary Pharmacology & Therapeutics, 1995
- Epidemiology and Natural History of Gastro-Oesophageal Reflux DiseaseDigestion, 1992